Stocktoria
Arcutis Biotherapeutics, Inc. ARQT
Arcutis Biotherapeutics, Inc. (ARQT) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $376.1M at a -4.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.53 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-07 | Needham | Buy (reit) |
| 2026-03-02 | Mizuho | Outperform (main) |
| 2026-02-27 | Guggenheim | Buy (main) |
| 2026-02-26 | TD Cowen | Buy (main) |
| 2026-02-26 | HC Wainwright & Co. | Buy (main) |
| 2026-02-26 | Needham | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.65 |
| Retained earnings / assets | -2.629 |
| EBIT / assets | -0.028 |
| Equity / liabilities | 0.778 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | 4/9 | -3.68 | — | +91.3% |
| SVA | SINOVAC BIOTECH LTD | 3/9 | 8.06 | — | +6.8% |
| ESPR | Esperion Therapeutics, Inc. | 3/9 | -8.63 | — | +21.3% |
| MNKD | MANNKIND CORP | 3/9 | -11.89 | 218.2 | +22.2% |
| ARDX | ARDELYX, INC. | 2/9 | -2.34 | — | +22.1% |
| INVA | Innoviva, Inc. | 3/9 | 6.59 | — | +14.7% |
| CRMD | CorMedix Inc. | 5/9 | 3.07 | 3.8 | +617% |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
FAQ
Is ARQT financially healthy?
Arcutis Biotherapeutics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ARQT pay a dividend?
No, Arcutis Biotherapeutics, Inc. does not currently pay a dividend.
How profitable is ARQT?
In FY2025, Arcutis Biotherapeutics, Inc. had a net margin of -4.3% and a return on equity of -8.5%.
What is the analyst price target for ARQT?
The average Wall-Street price target for Arcutis Biotherapeutics, Inc. is $34.62, about 31.8% above the recent price, from 8 analysts (consensus: strong buy).
Is ARQT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Arcutis Biotherapeutics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.